Tyme Applied Sciences Inc Tyme Inventory Worth Forecast & Target

0
31

Tyme Technologies, Inc. operates as a biotechnology company, which engages in the growth and commercialization of most cancers therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that goals to disrupt the most cancers cell’s protein synthesis. The company was based by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ.

Tyme Technologies’ inventory is owned by a wide range of retail and institutional investors. Top institutional investors embody Kercheville Advisors LLC (0.06%), Simplex Trading LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Cutler Group LP (0.00%). Company insiders that personal Tyme Technologies inventory include Barbara Galaini, David Carberry, Diana F Cantor, Douglas A Michels, James Biehl, Michael Demurjian, Steve Hoffman, Tornout Jan M Van and Tornout Jan M Van. View institutional possession tendencies for Tyme Technologies. In 2025, TYME is forecast to generate $51,708,564,061 in income, with the bottom revenue forecast at $51,708,564,061 and the highest revenue forecast at $51,708,564,061.

This means that if you invested $100 now, your current funding could also be price 0$ on 2023 May 10, Wednesday. By making a free account, you comply with our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. One share of TYME stock can at present be bought for approximately $0.28. The P/E ratio of Tyme Technologies is -1.ninety nine, which means that its earnings are negative and its P/E ratio can’t be compared to firms with constructive earnings.

The profitable prediction of Tyme Technologies stock worth could yield a significant revenue to buyers. The efficient-market speculation suggests that each one printed inventory costs of traded companies, similar academy sports augusta to Tyme Technologies, already reflect all publicly obtainable info. This educational assertion is a elementary principle of many monetary and investing theories used today.

Unable to gauge TYME’s dividend yield against the highest 25% of dividend payers, as the corporate has not reported any latest payouts. Unable to evaluate TYME’s dividend yield in opposition to the underside 25% of dividend payers, as the corporate has not reported any latest payouts. This is quite a rare state of affairs as 97% of firms covered by SimplyWall St do have previous financial knowledge.